Table 1.
Age of participants at screening in the Phase 1a unboosted multiple ascending dose cohorts (Cohorts 7 & 8) and the cobicistat-boosted single ascending dose cohorts (Cohorts 11, 12 and 13).
| Cohort 7 (300 mg × 3 QD)aN = 3 | Cohort 8 (600 mg × 3 QD)bN = 6 | Total | Cohort 11 (75 mg SJ733+150 mg cobicistat SAD)cN = 6 | Cohort 12 (300 mg SJ733+150 mg cobicistat SAD)dN = 6 | Cohort 13 (600 mg SJ733+150 mg cobicistat SAD) N = 6 | Total | |
|---|---|---|---|---|---|---|---|
|
Mean Range |
31·9 27·5 – 47·2 |
27·0 19·1 – 37·6 |
29·5 19·1 – 47·2 |
25·6 19·5 – 38·1 |
30·3 (21·3 – 47·95) |
23·2 (18·8 – 30·8) |
26·4 (18·8 – 47·95) |
a
Includes 3 subjects who participated in previous single-dose cohorts. One subject participated in cohort 4 and the fed cohort; one participated in cohort 5; and one participated in cohort 6.
b
Includes 5 subjects who participated in previous single-dose cohorts.
c
Includes 6 subjects who participated in previous dose cohorts.
d
Includes 2 subjects who participated in previous dose cohorts.